Skip to content
OpenCapital
Get started
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings

VTGN·Reported February 12, 2026·After market close

Vistagen Therapeutics, Inc. reported Q4 2025 revenue of $303.0K (+29.5% YoY), missed analyst consensus of $364.4K by $61.4K. Diluted EPS came in at $-0.45 (+2.2% YoY), beat the $-0.51 consensus by $0.06.

Revenue
$303.0Kmissed by $61.4K
Consensus: $364.4K
Diluted EPS
$-0.45beat by $0.06
Consensus: $-0.51
SEC

SEC Filings

Earnings release8-K · 0001628280-26-007715
Quarterly report10-Q · 0001628280-26-007718

Financial Snapshot

Trailing eight quarters through Q4 2025

View all metrics

Q4 2025 Earnings FAQ

Common questions about Vistagen Therapeutics, Inc.'s Q4 2025 earnings report.

Vistagen Therapeutics, Inc. (VTGN) reported Q4 2025 earnings on February 12, 2026 after market close.

Vistagen Therapeutics, Inc. reported revenue of $303.0K and diluted EPS of $-0.45 for Q4 2025.

Revenue missed the consensus estimate of $364.4K by $61.4K. EPS beat the consensus estimate of $-0.51 by $0.06.

Compared to the same quarter a year prior, revenue grew 29.5% from $234.0K a year earlier and diluted EPS grew 2.2% from $-0.46.

You can read the 8-K earnings release (0001628280-26-007715) and the 10-Q periodic report (0001628280-26-007718) directly on SEC EDGAR. The filing index links above go to sec.gov.